Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,025 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia of the Alzheimer's Type Clear all
Enrolling by invitation No phase listed Observational

Feasibility of Lecanemab Registry and Clinical Outcome Measures

NCT06285448
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lecanemab
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

NCT04079803
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting Not applicable Interventional

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

NCT06411561
View directory record Official record
Conditions
Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
Interventions
SLEEP + COG, COG, SLEEP, AC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Cataract Removal and Alzheimer's Disease

NCT00921297
View directory record Official record
Conditions
Cataracts, Alzheimer's Disease
Interventions
Immediate Cataract Surgery
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers

NCT05202223
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Interventions
Harmony at HOME (H@H)
Behavioral
Lead sponsor
Elizabeth K Rhodus
Other
Eligibility
21 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

NCT02646982
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo, Candesartan
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
View directory record Official record
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1Phase 2 Interventional

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

NCT05189106
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Baricitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Old School Hip Hop: Parent Follow-Up & Spanish Speakers Inclusion

NCT06699589
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Old SCHOOL Hip-Hop (Dementia Education), My Plate (Nutrition Education)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
Drug
Lead sponsor
GemVax & Kael
Industry
Eligibility
55 Years to 85 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jun 10, 2026, 2:13 PM EDT
Active, not recruiting Phase 2 Interventional

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

NCT03649724
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02788513
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Colton, California • Long Beach, California • Redlands, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated No phase listed Observational

Autonomous Navigating Robot for Detecting Falls and Risk of Falls in Nursing Home Residents With Alzheimer Disease/ADRD - Feasibility Study

NCT07451223
View directory record Official record
Conditions
Fall in Nursing Home
Interventions
Not listed
Lead sponsor
Vigorous Mind, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

NCT05060848
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
55 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Mobile Informatics Solution to Aid in Memory

NCT04700540
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Smartwatch Reminder (SR) system
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Withdrawn Not applicable Interventional

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

NCT04440891
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TMS stimulation with X-Torp task, TMS-Stimulation with MindMotion Go, TMS-Sham with X-Torp task, TMS-Sham with MindMotion Go
Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

NCT03491150
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
32
States / cities
Newport Beach, California • Redlands, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2012 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated No phase listed Observational

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:

NCT03360019
View directory record Official record
Conditions
Dementia, Vascular, Alzheimer Dementia, Lewy Body Dementia With Behavioral Disturbance
Interventions
Activlink insole, Activlink Phone Application
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 10, 2026, 2:13 PM EDT